In addition, Avelumab, an anti-PD-L1 antibody, presents with an acceptable safety profile and clinical activity in patients with locally advanced or metastatic BC; high PD-L1 expression in tumor-associated immune cells predicts an elevated possibility of clinical response to Avelumab in metastatic BC [17]. This evidence concerns the gene CD274 and neoplasm.